ITMI920162A0 - Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole - Google Patents

Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole

Info

Publication number
ITMI920162A0
ITMI920162A0 IT92MI162A ITMI920162A ITMI920162A0 IT MI920162 A0 ITMI920162 A0 IT MI920162A0 IT 92MI162 A IT92MI162 A IT 92MI162A IT MI920162 A ITMI920162 A IT MI920162A IT MI920162 A0 ITMI920162 A0 IT MI920162A0
Authority
IT
Italy
Prior art keywords
activity
maintaining
polyethylene glycol
proteolytic enzymes
enzymes modified
Prior art date
Application number
IT92MI162A
Other languages
English (en)
Inventor
Francesco Maria Veronese
Paolo Caliceti
Addone Schiavon
Luciana Sartore
Original Assignee
Cnr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cnr filed Critical Cnr
Priority to ITMI920162A priority Critical patent/IT1260468B/it
Publication of ITMI920162A0 publication Critical patent/ITMI920162A0/it
Priority to PCT/EP1993/000205 priority patent/WO1993015189A1/en
Priority to JP5512940A priority patent/JPH07502900A/ja
Priority to CA002129134A priority patent/CA2129134A1/en
Priority to EP93914525A priority patent/EP0624191A1/en
Priority to US08/256,834 priority patent/US5514572A/en
Priority to AU34522/93A priority patent/AU665982B2/en
Publication of ITMI920162A1 publication Critical patent/ITMI920162A1/it
Application granted granted Critical
Publication of IT1260468B publication Critical patent/IT1260468B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ITMI920162A 1992-01-29 1992-01-29 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole IT1260468B (it)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ITMI920162A IT1260468B (it) 1992-01-29 1992-01-29 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
PCT/EP1993/000205 WO1993015189A1 (en) 1992-01-29 1993-01-29 A method to maintain the activity in polyethylene glycol-modified proteolytic enzymes
JP5512940A JPH07502900A (ja) 1992-01-29 1993-01-29 ポリエチレングリコール変性タンパク分解酵素の活性を持続させる方法
CA002129134A CA2129134A1 (en) 1992-01-29 1993-01-29 A method to maintain the activity in polyethylene glycol-modified proteolytic enzymes
EP93914525A EP0624191A1 (en) 1992-01-29 1993-01-29 A method to maintain the activity in polyethylene glycol-modified proteolytic enzymes
US08/256,834 US5514572A (en) 1992-01-29 1993-01-29 Method to maintain the activity in polyethylene glycol-modified proteolytic enzymes
AU34522/93A AU665982B2 (en) 1992-01-29 1993-01-29 A method to maintain the activity in polyethylene glycol-modified proteolytic enzymes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI920162A IT1260468B (it) 1992-01-29 1992-01-29 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole

Publications (3)

Publication Number Publication Date
ITMI920162A0 true ITMI920162A0 (it) 1992-01-29
ITMI920162A1 ITMI920162A1 (it) 1993-07-30
IT1260468B IT1260468B (it) 1996-04-09

Family

ID=11361713

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI920162A IT1260468B (it) 1992-01-29 1992-01-29 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole

Country Status (7)

Country Link
US (1) US5514572A (it)
EP (1) EP0624191A1 (it)
JP (1) JPH07502900A (it)
AU (1) AU665982B2 (it)
CA (1) CA2129134A1 (it)
IT (1) IT1260468B (it)
WO (1) WO1993015189A1 (it)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
AU697440B2 (en) * 1994-12-07 1998-10-08 Novozymes A/S Polypeptide with reduced allergenicity
JPH11502255A (ja) * 1995-12-29 1999-02-23 ザ、プロクター、エンド、ギャンブル、カンパニー 固定化酵素を含有する洗剤組成物
US6008037A (en) * 1996-11-14 1999-12-28 Polymer Technology Corporation Use of water soluble enzyme-polymer conjugates for cleaning contact lenses
US6416756B1 (en) 1997-01-10 2002-07-09 Novozymes A/S Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
CN1246891A (zh) * 1997-02-06 2000-03-08 诺沃挪第克公司 添加和/或除去了连接基团的多肽－聚合物偶联物
US6548644B1 (en) * 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
BR9909130A (pt) 1998-03-26 2000-12-19 Procter & Gamble Variantes de protease de serina tendo substituições de amino-ácido
CA2330859A1 (en) 1998-05-08 1999-11-18 University Of Southern California Size enhanced fibrinolytic enzymes
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
CZ2002220A3 (cs) 1999-07-22 2002-05-15 The Procter & Gamble Company Varianty subtilisinové proteasy s delecemi a substitucemi aminokyselin v definovaných epitopových regionech
MXPA02000840A (es) 1999-07-22 2002-07-30 Procter & Gamble Variantes de proteasa de subtilisina que tienen substituciones de aminoacidos en regiones de epitopes definidas.
CA2379729A1 (en) 1999-07-22 2001-02-01 The Procter & Gamble Company Protease conjugates having sterically protected clip sites
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6969515B2 (en) 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
CA2457876C (en) 2001-08-22 2011-10-11 Bioartificial Gel Technologies Inc. Process for the preparation of activated polyethylene glycols
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP2322229B1 (en) 2001-10-10 2016-12-21 Novo Nordisk A/S Remodeling and glycoconjugation of Factor IX
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
EP2292271A3 (en) 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
NZ542094A (en) 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
AU2004240553A1 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US7662607B2 (en) * 2003-07-30 2010-02-16 New Century Pharmaceuticals, Inc. Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
CN101072789B (zh) 2004-01-08 2013-05-15 生物种属学股份公司 肽的o-连接的糖基化
MXPA06008496A (es) 2004-02-02 2007-01-30 Ambrx Inc Polipeptidos de interferon humano modificados y sus usos.
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2009100255A2 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
BRPI0518661A2 (pt) 2004-12-22 2008-12-02 Ambrx Inc mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
ATE541934T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
MX2007007580A (es) 2004-12-22 2007-12-11 Ambrx Inc Hormona del crecimiento humana modificada.
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP1893229B1 (en) 2005-06-03 2011-10-19 Ambrx, Inc. Improved human interferon molecules and their uses
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20070092925A1 (en) * 2005-10-25 2007-04-26 Conopco, Inc., D/B/A Unilever Method of treating skin by delivering specific protein stabilizers/protectors to skin proteins and methods of selecting said stabilizers
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
PT2339014E (pt) 2005-11-16 2015-10-13 Ambrx Inc Métodos e composições compreendendo aminoácidos não-naturais
JP2009544327A (ja) 2006-07-21 2009-12-17 ノヴォ ノルディスク アー／エス Ｏ−結合型グリコシル化配列によるペプチドのグリコシル化
CN106008699A (zh) 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
CA2662753C (en) 2006-09-08 2016-02-23 Ambrx, Inc. Hybrid suppressor trna for vertebrate cells
US8420792B2 (en) 2006-09-08 2013-04-16 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
AU2007319657B9 (en) 2006-10-04 2019-10-31 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
ITRM20060682A1 (it) * 2006-12-19 2008-06-20 Sicit Chemitech S P A Nuovi derivati polimerici biodegradabili
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
KR20150064246A (ko) 2007-04-03 2015-06-10 바이오제너릭스 게엠베하 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
JP5547083B2 (ja) 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
CN101965200B (zh) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
CN107022020A (zh) 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
MX348657B (es) 2008-09-26 2017-06-21 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
EP2440239B1 (en) 2009-06-09 2017-09-13 Prolong Pharmaceuticals, LLC Hemoglobin compositions
CN102482338B (zh) 2009-07-10 2016-09-28 斯路姆基因公司 纤溶酶原和纤溶酶的变体
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
CA2784800A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
AU2010341516B2 (en) 2009-12-21 2014-01-16 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
SG10201506443TA (en) 2010-08-17 2015-10-29 Ambrx Inc Modified relaxin polypeptides and their uses
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
KR20140015289A (ko) 2011-01-05 2014-02-06 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민 변이체
CN103764163A (zh) 2011-08-12 2014-04-30 斯路姆基因公司 纤溶酶原和纤溶酶变体
SG11201408161RA (en) 2012-06-08 2015-01-29 Sutro Biopharma Inc Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2611788T3 (es) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
SI3584255T1 (sl) 2012-08-31 2022-05-31 Sutro Biopharma, Inc Modificirane aminokisline, ki vsebujejo azido skupino
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
LT3412302T (lt) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
CA3111576A1 (en) 2018-09-11 2020-03-19 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
US20220096608A1 (en) * 2019-01-25 2022-03-31 Council Of Scientific And Industrial Research Fibrinolytic composition and method of its preparation
KR20220151202A (ko) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4610879A (en) * 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5219995A (en) * 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification

Also Published As

Publication number Publication date
CA2129134A1 (en) 1993-08-05
US5514572A (en) 1996-05-07
JPH07502900A (ja) 1995-03-30
AU3452293A (en) 1993-09-01
EP0624191A1 (en) 1994-11-17
ITMI920162A1 (it) 1993-07-30
WO1993015189A1 (en) 1993-08-05
AU665982B2 (en) 1996-01-25
IT1260468B (it) 1996-04-09

Similar Documents

Publication Publication Date Title
ITMI920162A0 (it) Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
MC2313A1 (fr) Inhibiteurs d'enzymes
ITRM950861A0 (it) Procedimento per l'assemblaggio di semilavorati per calze-mutanda
ITMI930195A1 (it) Derivati di esteri arilacetici ad attivita' fungicida
ITMI932343A1 (it) Procedimento per l'isolamento e la purificazione di mevinolina
ITRM940210A1 (it) Procedimento per la purificazione di soluzioni di policarbunati e di poliestercarbonati
ITMI920228A0 (it) Tiazolilpirroli ad attivita' fungicida
ITRM920217U1 (it) Insieme di croce e mozzo di trascinamento per giunto cardanico.
ITMI921659A0 (it) Nuovi composti ad attivita' analgesica e nootropa
ITMI921950A0 (it) Composizioni farmaceutiche ad attivita' epato-trofica ed anti-aging
ITMI940604V0 (it) Sopralzo per l'appoggio di cibarie e l'alloggiamento di bottiglie
ITMI930771A0 (it) Comosiziomi farmaceutiche ad attivita' antitossica
ITMI932153A0 (it) Peptidi retroinvertiti ad attivita' immunomodulatrice
ITMI932446A1 (it) Piridotiazine e piridotiazepine ad attivita' antiasmatica
ITMI930453A1 (it) Composizione farmaceutica avente attivita' antiasmatica
ITMI920947A0 (it) Chinazoloni ad attivita' cardiovascolare
ITRM930511A0 (it) Biosensore enzimatico ad elevata attivita' e procedimento per la realizzazione di detto.
ES1022985Y (es) Conjunto de soportes y carril de apoyo.
LT2578B (lt) Saudymo taikinys
ITMI921862A1 (it) Tiazolidine ad attivita' cardiovascolare
ITMI941820A0 (it) Sopralzo per l'appoggio di cibarie e l'alloggiamento di bottiglie
ITMI921252A0 (it) Composizione farmaceutica ad attivita' antitosse
ITMI930218A1 (it) Derivato peptidico della rimantadina di attivita' immunomodulante
ITBO930005V0 (it) "contenitore-espositore di piatti per vivande"
IT9083487A0 (it) Sistema per la gestione ed il controllo di entita' organizzate

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960130